Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
561. |
ECCT/11/01/02 | EARNEST EARNEST : Europe -Africa Research Network for Evaluation of Second-line Therapy |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
06-09-2010 |
View |
562. |
ECCT/10/11/06 | Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy A5264/AMC 067 "A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Li1mited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)" |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Walter Reed Project Kericho (Kericho county) 2. Moi University Clinical Research Centre (Uasin Gishu county) |
04-08-2010 |
View |
563. |
ECCT/10/11/03 | ASMQ Study Efficacy, Safety and Population-Pharmacokinetics of Artesunate-Mefloquine Combination for the Treatment of Uncomplicated Falciparum Malaria in African Children versus Artemether-Lumefantrine |
Principal Investigator(s) 1. Bearnhards Ogutu Ragama Site(s) in Kenya The Kenya Medical Research Institute (KEMRI), Kisumu, Kenya |
07-02-2011 |
View |
564. |
ECCT/10/09/05 | A5225/ HiFLAC A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) |
Principal Investigator(s) 1. Deborah Chepngeno langat Site(s) in Kenya 1. |
08-02-2013 |
View |
565. |
ECCT/10/09/03 | A0661201 A0661201 AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA |
Principal Investigator(s) 1. Joshua Kimani Site(s) in Kenya University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital |
25-09-2013 |
View |
566. |
ECCT/10/05/02 | AERAS-402 A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter, Proof-of-concept Study to Evaluate the Safety and Efficacy of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis |
Principal Investigator(s) 1. Dr Videlis Nduba 2. Dr Grace Kiringa Kaguthi Site(s) in Kenya KEMRI-CDC |
24-06-2010 |
View |
567. |
ECCT/10/03/03 | High-Dose Fluconazole Treatment in AIDS-Associated CM A5225/HiFLAC: A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
11-05-2012 |
View |
568. |
ECCT/09/09/02 | MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN |
Principal Investigator(s) 1. LUCAS OTIENO TINA 2. MARY HAMEL Site(s) in Kenya 1. KEMRI-CDC, (Siaya county) 2. KEMRI-WRP (Kisumu county) |
24-06-2010 |
View |
569. |
ECCT/09/06/02 | A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples |
Principal Investigator(s) 1. Lisa Ann Mills Site(s) in Kenya Kisumu, Kenya |
05-07-2012 |
View |
570. |
ECCT/09/03/01 | REMoxTB A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis |
Principal Investigator(s) 1. Evans Inyangala Amukoye Site(s) in Kenya Kibera D.O Health Centre |
01-07-2013 |
View |